Target intelligence / Profile preview

Preferentially expressed antigen in melanoma-derived peptide-human leukocyte antigen complexes (PRAME-pHLA complexes)

Target
PRAME-pHLA complexes
Molecular classification
Receptor, Other
01

Overview

Preferentially expressed antigen in melanoma (PRAME)-derived peptide-human leukocyte antigen (HLA) complexes represent a class of tumor-associated antigens presented on the cell surface of various malignancies. PRAME is a cancer-testis antigen that is highly expressed in a wide range of solid tumors (such as melanoma, non-small cell lung cancer, ovarian cancer, and synovial sarcoma) and hematological malignancies (such as acute myeloid leukemia), while its expression in healthy tissues is restricted to immune-privileged sites like the testes and endometrium. Intracellular PRAME proteins are degraded by the immunoproteasome into peptide fragments, such as the ALYVDSLFFL (ALY) or SLLQHLIGL peptides, which are then loaded onto HLA class I molecules (most commonly HLA-A*02:01 or HLA-A*24:02) and transported to the cell surface. These peptide-HLA complexes serve as highly specific targets for the immune system, allowing T-cell receptors (TCRs) to recognize and eliminate cancer cells. Therapeutic strategies targeting these complexes include adoptive T-cell therapies, TCR-mimic chimeric antigen receptor (CAR) T-cells, and bispecific T-cell engagers. These agents bind specifically to the PRAME-pHLA complex, redirecting and activating T-cells to induce tumor cell cytolysis. Clinical development of these therapies requires patient selection based on both PRAME expression and specific HLA haplotype matching (e.g., HLA-A*02:01). Notable safety concerns associated with these therapies include cytokine release syndrome (CRS), cytopenias from pre-conditioning lymphodepletion, and potential on-target off-tumor toxicities, although the restricted expression of PRAME in normal tissues generally provides a favorable therapeutic window.

Other names
PRAME-derived peptide-HLA complexesPRAME-pHLA complexesPRAME-HLA complexesPRAME peptide-MHC complexesPreferentially expressed antigen in melanoma peptide-HLA complexesPRAME-HLA-A*02:01 complexesPRAME-HLA-A2 complexesPRAME-HLA-A*24:02 complexes
02

Mechanism of action

Drugs targeting PRAME-derived peptide-HLA complexes work by redirecting the host immune system to recognize and destroy cancer cells. This is achieved through several modalities: adoptive T-cell receptor (TCR) T-cell therapies (which use patient-derived T-cells engineered with high-affinity TCRs), TCR-mimic chimeric antigen receptor (CAR) T-cells, and bispecific T-cell engagers (which bridge the tumor's peptide-HLA complex with CD3 on T-cells to trigger direct cytolysis).

03

Biological functions

Immune responseAntigen presentationOther
04

Disease associations

Cancer
05

Safety considerations

Cytokine release syndrome (CRS)Immune effector cell-associated neurotoxicity syndrome (ICANS)On-target off-tumor toxicityCytopeniasT-cell exhaustionTumor escape mechanisms
06

Interacting drugs

5 more in the full profile.

07

Biomarkers

PRAME expressionHLA-A*02:01 positivityHLA-A*24:02 positivityCirculating tumor DNA (ctDNA) levelsInterferon-gamma (IFN-gamma) levels

Beyond the preview

Go deeper on Preferentially expressed antigen in melanoma-derived peptide-human leukocyte antigen complexes (PRAME-pHLA complexes).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Preferentially expressed antigen in melanoma-derived peptide-human leukocyte antigen complexes (PRAME-pHLA complexes).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call